Artificial intelligence (AI) is increasingly seen in the biomedical and life sciences as a tool to improve drug development. As one of the world's largest companies, Google is very interested in the application of artificial intelligence in the medical field. According to Dr. Greg Corrado, a neuroscientist at Google, the basic technology of machine learning and artificial intelligence is suitable for a variety of tasks, including tasks in people’s daily life, such as asking for directions or organizing emails, as well as dealing tasks that doctors, nurses and clinicians face every day.

Verily, a subsidiary of Alphabet, focuses on the health field. One of the company's ongoing projects is software that can diagnose diabetic retinopathy, which can lead to blindness. The company is also working to develop contact lenses that can monitor the blood sugar of diabetic patients.

Dr. Jessica Mega, a cardiologist at Verily's chief medical officer, said: "In every case, you can use new technologies and tools to solve problems that are encountered. For surgical robots, the idea of learning during surgery from one to another becomes very important because we should continue to get better."

Earlier this year, Google's DeepMind won a Global Assessment of Structural Predictions (CASP) sponsored by the National Institute of Integrated Medical Sciences (NIH/NIGMS) and hosted by the Protein Structure Prediction Center. This is a global competition that has been held every two years since 1994.

Proteins have a three-dimensional structure that is an important factor in determining their function. For example, it is common for a protein's gene mutation to cause the protein to have a different shape, making the protein function abnormal or even no longer express at all. The shape of the protein is also dynamic, switching between different states.

In CASP, participants attempt to predict the three-dimensional shape of a particular human protein. Researchers in related fields use a variety of methods to solve the problem. DeepMind not only beat other scientists in the competition, but also gave predictions that were almost twice as accurate as expert’s predictions.

According to Dr. Derek Lowe, who wrote for the Pipeline column for Science Translational Medicine, It's not that machines replace chemists, but chemists who use machines will replace chemists who don't use machines.

Other companies outside of Google focus on artificial intelligence and machine learning. Headquartered in Salt Lake City, Utah, Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence, experimental biology, and automation to focus on large-scale discovery and development of drugs.

In January, Recursion announced its collaboration with Takeda Pharmaceutical in identifying new preclinical candidates for rare diseases. Over the course of 18 months, this partnership led to the assessment of unique indications for more than 60 preclinical and clinical compounds of Takeda Pharmaceuticals and led to the discovery of new candidate treatments in more than six diseases.

San Francisco-based Atomwise uses artificial intelligence based on convolutional neural networks to find drugs, and convolutional neural networks are the same technology used in facial recognition and autonomous vehicles. Not long ago, Atomwise announced a partnership with DNDi to develop a first-in-class treatment for Chagas disease. This study has provided some very promising candidate compounds.

These are just two of the many examples. But Google is probably the largest and, of course, the most well-known data company in the world, bringing a lot of resources to this field. At least part of its focus is on the diagnosis of the patient directly. The hospital has a large number of patient data, including electronic health records, scans and test results. Dr. Mega said that these are the materials that the algorithm absorbs and processes, and it is possible for people to dig out more useful information.

Verily's project with Duke University and Stanford University is called Project Baseline, which hopes to recruit 10,000 volunteers to provide additional data for the company. In addition to performing various cardiac scans, blood tests, stress tests, and skin sampling, participants also filled out quarterly questionnaires, and staff placed a device under their mattress to track sleep patterns and required heart and motion monitors. .

This may sound like a violation of the privacy of the participants – after all, the company has access to your online search and purchase records, as well as other data – and this is one aspect of the project that may cause concern. But so far, users are willing to give up a certain degree of privacy for the computer convenience services provided by Google. This may also apply to their health problems.

As a trust-worthy chemical vendor for at least two decades, BOC Sciences keeps close watch on the latest trend and innovations in drug discovery, and at the same time, offers a comprehensive collection of chemicals such as checkpoint inhibitors as well as small molecule inhibitors like Leucyl-tRNA synthetase Inhibitor, LpxC Inhibitor, LSD1 Inhibitor, Lymphocyte function-associated antigen 1 Inhibitor, Penicillin-binding proteins Inhibitor, Plant Growth Regulator Inhibitor, Potassium voltage-gated channel Inhibitor, Prostacyclin Receptor Inhibitor, Sphingosine 1 Phosphate Receptor Inhibitor and more.

Author's Bio: 

BOC Sciences